## nature research

Corresponding author(s):	Anthony W Purcell
Last updated by author(s):	Oct 28, 2020

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_			
St	ati	cti	2

n/a	Confirmed
	$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🗴 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	🕱 A description of all covariates tested
	🕱 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F, t, r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	$oxed{x}$ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	<b>x</b> Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
	Our web collection on <u>statistics for biologists c</u> ontains articles on many of the points above.

## Software and code

Policy information about availability of computer code

Data collection All

All LC-MS data was acquired on a Thermoscientific Q-Exactive Plus mass spectrometer using Xcaliber 3.0.63 acquisition software (ThermoScientific, San Jose, CA, USA).

Data analysis

PEAKS Studio® (v.10) (Bioinformatics Solutions Inc)

human UniprotKB database (v2019-08)

Skyline (v.4.2) (Maccoss laboratory, University of Washington, USA)

NNalign (Nielsen laboratory, DTU, Denmark) http://www.cbs.dtu.dk/services/NNAlign-2.0/

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

## Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data are available as Supplementary Data files or available from the corresponding authors upon reasonable request. The original mass spectrometry proteomics data, the PEAKS Studio® search results and the Skyline Report files have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifiers PXD017824 (C1R-A\*02:01 and C1R-B\*07:02 DDA LC-MS/MS) and PXD017839 (C1R-A\*02:01 and C1R-B\*07:02 DIA LC-MS/MS for thermal stability experiments and the experiments used to determine complete ablation of peptide recovery at high temperature).

Field-specific reporting				
<del></del>				
	one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences	☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences			
For a reference copy of	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scie	nces study design			
All studies must di	lisclose on these points even when the disclosure is negative.			
Sample size	n/a These are large sacle data acquisiotn studies sample size is not relevant here			
Data exclusions	No data was excluded from the analysis			
Replication	All measurements were made in biological triplicates			
Randomization	No randomization was required since the study involved direct measurement of biochemical parameters			
Blinding	Blinding is not relevant to the analysis in this study			
Reporting for specific materials, systems and methods  We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & experimental systems Methods				
n/a Involved in t	he study n/a Involved in the study			
Antibodie	The Antibodies The Chip-seq			
Eukaryoti	c cell lines Flow cytometry			
	Palaeontology and archaeology  MRI-based neuroimaging			
	nd other organisms			
	search participants			
Clinical da				
Dual use research of concern				
Antibodies				
Antibodies used	W6/32 (produced in house from well characterized hybridoma available from ATCC), goat F(ab')2 Anti- Mouse IgG(H + L) Human			
, websares asea	adsorbed-PE (Commercially sourced from Southern Biotech and Reacts with the heavy and light chains of mouse IgG1, IgG2a, IgG2b,			
	IgG2c, and IgG3 and with the light chains of mouse IgM and IgA), HLA-A*02:01-specific antibody BB7.2 (produced in house and available from ATCC (HB-82)).			
	, "			
Validation	Antibody specificity has been well documented in literature and specificty data is available on the vendors website for each batch.			
	Each purified batch is tested by flow cytometry			
Eukaryotic (	call lines			
Policy information about cell lines  Cell line source(s)  C1R.A2 (HLA-A*02:01 transfected C1R parental cell line), C1R.B7 (HLA-A*02:01 transfected C1R parental cell line)				
222 334. 32(3)	published reagents (see Faridi et al. Sci Immunol 3(28), eaar3947 (2018) and Purcell et al Nat Protocols 14, 1687–1707 (2019)).			
Authentication	HLA cell surface expression was rtoutinely montired by flow cytometry using the W6/32 antibody. The parental cells have been validated by RNASeq (Faridi et al. Sci Immunol 3(28), eaar3947 (2018))			

All cell line were free of mycoplasma as determined by sensitive PCR.

No commonly misidentified cell lines were used in the study.

Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)